N/A N=2 Safety of 4CMenB Exposure During Pregnancy
Infections, Meningococcal
Primary: Major Congenital Malformation (MCM)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=40 Measurement of Agricultural and Dietary Glyphosate Exposure Among Pregnant Women
Exposure to Herbicides
Primary: Specific Gravity-adjusted Urinary Glyphosate Concentrations During Conventional and Organic Diet — 0.19; 0.17; 0.18; 0.14 ug/L — p=0.17
N/A N=98 Clinical Follow-up and Outcomes of Pregnancies Exposed to Ella
Emergency Contraception
Primary: Number of Participants Who Experienced Assessed Pregnancy Outcomes — 1; 0; 1; 0 Participants
N/A N=103 Twinrix Pregnancy Registry
Hepatitis
Primary: Number of Outcomes From Pregnancies With Reported Exposure Within 28 Days of Last Menstrual Period — 0; 0; 0; 0 Pregnancy Outcomes
N/A N=305 Boostrix® Pregnancy Registry
Pertussis
Primary: Number of Participants With Known Pregnancy Outcomes, by Type of Pregnancy Outcomes in Women Intentionally or Unintentionally Vaccinated With Boostrix During Pregnancy…
Phase 4 N=14 Effects of Pregnancy-associated Hormones on THC Metabolism in Women
Pregnancy Related · Cannabis Use
Primary: Dronabinol Exposure — 7.0; 5.6; 5.1; 5.0 nM*h — p=>0.05
N/A N=534 Organization of Teratology Information Services (OTIS) Autoimmune Diseases in Pregnancy Project
Pregnancy
Primary: Percentage of Infants With Major Birth Defects in Pregnancies Ending With Live-born Infants — 9.4; 3.5 percentage of participants
N/A N=10 Phthalate and Bisphenol Exposure During Minipuberty
Phthalate Exposure · Bisphenol Exposure
Primary: Log Signal Intensity of Bisphenol A (BPA) in Child Urine Samples — 0.00; 5.43 Log(Arbitrary Units)
Phase 2 N=30 Project 4, Study 2: Extended Exposure to Low Nicotine Content Cigarettes in Pregnant Women
Tobacco Use Disorder
Primary: Total Cigarettes Per Day — 16.31; 18.36 Cigarettes per day
N/A N=65,783 The Safety of Boostrix Following Routine Immunization of Pregnant Women
Whooping Cough
Primary: Incidence Rate (Per 1000 Person-years) of Pre-specified Maternal Adverse Events for Exposed Cohort women-on or After 1st Day of 27th Week of Pregnancy and Unexposed…
N/A N=3,416 Lamotrigine Pregnancy Registry (LAM05)
Epilepsy · Bipolar Disorder
Primary: Birth Outcomes by Earliest Pregnancy Trimester of Exposure to Lamotrigine Monotherapy — 31; 4; 1; 0 infants
Phase 3 N=127 Fetal and Infant Effects of Maternal Buprenorphine Treatment
Neonatal Abstinence Syndrome
Primary: Fetal Heart Rate — 145.7; 143.3; 138.6; 136.3 beats per minute — p=0.001
N/A N=60 Computer-delivered Screening & Brief Intervention for Marijuana Use in Pregnancy
Marijuana Use · Pregnancy
Primary: Number of Participants Abstinent From Marijuana for the 7 Days Prior to Delivery — 6; 7; 6; 3 Participants
Phase 2 N=370 S. Japonicum and Pregnancy Outcomes
Schistosomiasis
Primary: Mean Newborn Birth Weight — 2.85; 2.85 kilograms — p=0.988
Phase 2 N=129 Placebo-controlled Trial of Bupropion for Smoking Cessation in Pregnant Women
Smoking · Nicotine Dependence
Primary: Number of Participants With Cessation Success at Week 10 After Target Quit Date — 12; 7 Participants with cessation success
N/A N=36 Rebif® Pregnancy Registry
Multiple Sclerosis
Primary: Spontaneous Abortion — 2; 0 Participants
Phase 2 N=47 Lutein & Zeaxanthin in Pregnancy - Carotenoid Supplementation During Pregnancy: Ocular and Systemic Effects
Nutrient Deficiency · Pregnancy Related
Primary: Change in Maternal Macular Carotenoid Levels From Enrollment to Birth of Infant — 12244; 7343 unitless
N/A N=1,195 Evaluation of Pre-Exposure Prophylaxis (PrEP) in Pregnant and Breastfeeding Women
HIV-I Infection
Primary: Participants Initiating Pre-exposure Prophylaxis During Pregnancy — 1089 Participants
N/A N=885,185 Varenicline Pregnancy Cohort Study
Malformations
Primary: Number of Infants With Major Congenital Malformations — 12; 3382; 33950 infants
Phase 2 N=775 Project 1, Study 2: Extended Exposure to Low Nicotine Content Cigarettes in Childbearing Age Women
Tobacco Use Disorder
Primary: Cigarettes Per Day (CPD) — 25.28; 19.95; 17.74 cigarettes per day — p=<0.0001
N/A N=396 Babies Living Safe and Smokefree
Second Hand Tobacco Smoke · Nicotine Dependence
Primary: Child Urine Cotinine — 1.00; .97; 1.09; 1.00 log transformed ng/mL
N/A N=33 Effects of Light on Melatonin and Contractions in Pregnant Women
Pregnancy
Primary: Melatonin Area Under the Curve (AUC) — 42.1; 24.3; 38.5; 26.3 area under curve (h*pg/mL) — p=0.334
Phase 4 N=137 Nicotine Replacement for Smoking Cessation During Pregnancy
Nicotine Dependence · Smoking Cessation
Primary: Number of Participants Who Self Report an Average of Zero Cigarettes Smoked Per Day in Preceding 7 Days — 12; 7 Participants
N/A N=360 Participate While Pregnant Survey
Pregnancy
Primary: Willingness to Participate in Research While Pregnant — 319; 39; 288; 70 Participants
N/A N=10 Pilot Study of Nicotine Replacement for Smoking Cessation During Pregnancy
Tobacco Use Disorder
Primary: Number of Days of Inhaler Use — 26.4 days
Phase 1 N=22 A Study in Pregnant Women With Chronic Inflammatory Diseases Treated With Cimzia (Certolizumab Pegol)
Rheumatoid Arthritis · Psoriatic Arthritis · Crohn's Disease
Primary: Predose and Postdose Plasma Certolizumab Pegol (CZP) Concentrations in Women During Pregnancy, Relative to Postpartum — 15.251; NA; 16.916; 9.027 microgram per…
N/A N=212 Intrapartum Maternal Oxygen Supplementation: Effects on the Mother and Neonate
Intrauterine Resuscitation
Primary: Umbilical Artery Malondialdehyde — 9.8; 10.2 umol/L
N/A N=79 Assessing the Drug Exposure Risk of Infants Breastfed by Women With Inflammatory Bowel Disease
Crohn's Disease · Ulcerative Colitis · Healthy Controls
Primary: Levels of TNF (Tumor Necrosis Factor Alpha) and TNF-dependent Chemokines (MCP1, MIP-1beta and IP10) in Breast Milk of Women With IBD and Healthy Controls by Multiplex…
N/A N=163 Impacts of Clinician-Mediated Report-Back
Health Knowledge, Attitudes, Practice
Primary: Knowledge Before and After Report-back Intervention. — 0.06; 0.02 Scores on a scale
Phase 1 N=41 Pharmacokinetics of Atazanavir/Ritonavir in HIV-1 Infected Pregnant Women
HIV Infection
Primary: Infant Gestational Age at Delivery — 38; 38 Weeks